$697.27 Million in Sales Expected for Catalent Inc (NYSE:CTLT) This Quarter
Wall Street brokerages expect that Catalent Inc (NYSE:CTLT) will announce $697.27 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Catalent’s earnings, with the highest sales estimate coming in at $707.80 million and the lowest estimate coming in at $690.70 million. Catalent posted sales of $623.00 million in the same quarter last year, which indicates a positive year over year growth rate of 11.9%. The company is expected to report its next earnings report on Tuesday, February 4th.
According to Zacks, analysts expect that Catalent will report full-year sales of $2.86 billion for the current year, with estimates ranging from $2.84 billion to $2.88 billion. For the next year, analysts forecast that the company will post sales of $3.06 billion, with estimates ranging from $3.03 billion to $3.10 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Catalent.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.19 by $0.07. Catalent had a net margin of 5.77% and a return on equity of 15.30%. The company had revenue of $664.70 million for the quarter, compared to analyst estimates of $634.87 million. During the same period in the prior year, the company earned $0.28 earnings per share. The firm’s revenue was up 20.5% on a year-over-year basis.
In other news, insider Aristippos Gennadios sold 45,256 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $52.55, for a total transaction of $2,378,202.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gregory T. Lucier purchased 2,000 shares of Catalent stock in a transaction that occurred on Monday, September 9th. The shares were bought at an average price of $51.64 per share, with a total value of $103,280.00. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 145,287 shares of company stock worth $7,275,066. Corporate insiders own 1.30% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Arizona State Retirement System raised its position in shares of Catalent by 1.1% during the 2nd quarter. Arizona State Retirement System now owns 105,756 shares of the company’s stock worth $5,733,000 after purchasing an additional 1,183 shares during the last quarter. Strs Ohio raised its position in shares of Catalent by 9.4% during the 2nd quarter. Strs Ohio now owns 5,902 shares of the company’s stock worth $319,000 after purchasing an additional 505 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new position in shares of Catalent during the 2nd quarter worth about $849,000. Virginia Retirement Systems ET AL raised its position in shares of Catalent by 19.3% during the 2nd quarter. Virginia Retirement Systems ET AL now owns 22,300 shares of the company’s stock worth $1,209,000 after purchasing an additional 3,600 shares during the last quarter. Finally, Ironvine Capital Partners LLC acquired a new position in shares of Catalent during the 2nd quarter worth about $13,581,000.
CTLT stock opened at $51.43 on Tuesday. The company’s 50-day simple moving average is $50.15 and its 200-day simple moving average is $51.31. The company has a quick ratio of 1.65, a current ratio of 2.06 and a debt-to-equity ratio of 1.73. Catalent has a 52-week low of $29.23 and a 52-week high of $58.38. The firm has a market cap of $7.61 billion, a P/E ratio of 31.75, a PEG ratio of 2.57 and a beta of 1.68.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Story: Do stock splits help investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.